Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Sankyo Buyout
This article was originally published in PharmAsia News
Executive Summary
Bidding by multiple companies and strong data for a late-stage, targeted melanoma drug helped drive Daiichi Sankyo Company Limited's eye-popping $805 million acquisition of privately-held Plexxikon Inc.
You may also be interested in...
Daiichi Sankyo Teams With National Cancer Center For Japanese Drug Discovery
Under the agreement, Japan’s National Cancer Center will provide the company with clinical research results and drug targets.
Daiichi Sankyo New R&D Head Puts Emphasis On Faster Decision-making
Daiichi Sankyo has four large Phase III milestones in the next two years, followed by prioritization for early stage programs
Cash-rich Japanese Pharma Now In A Position To Snatch Up Compounds, But Many Face Decision-making Bottlenecks - BIO Japan
YOKOHAMA, Japan - The impact of the strong yen appreciation has been severe for Japanese companies, contributing to sales dips as foreign markets balked at the rising prices for Japanese products. But the strong yen can also be a positive for Japanese consumers, including Japan Pharma shopping around for early-stage biotech compounds